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1.0 Introduction 
 
In May 2002, the United States Department of Energy (DOE) signed Assistance 
Instrument Number DE-FC09-02CH11109 with the Medical University of South 
Carolina (MUSC) to support the Environmental Biosciences Program (EBP).  This 
funding instrument replaces DOE Assistance Instrument Number DE-FC02-98CH10902. 
 
EBP is an integrated, multidisciplinary scientific research program, employing a range of 
research initiatives to identify, study and resolve environmental health risks.  These 
initiatives are consistent with the MUSC role as a comprehensive state-supported health 
sciences institution and with the nation’s need for new and better approaches to the 
solution of a complex and expansive array of environment-related health problems. 
 
The intrinsic capabilities of a comprehensive health sciences institution enable MUSC to 
be a national resource for the scientific investigation of environmental health issues.  
EBPs success as a nationally prominent research program is due, in part, to its ability to 
task-organize scientific expertise from multiple disciplines in addressing these complex 
problems 
 
Current research projects have focused EBP talent and resources on providing the 
scientific basis for risk-based standards, risk-based decision making and the accelerated 
clean-up of widespread environmental hazards.  These hazards include trichloroethylene 
and low-dose ionizing radiation.   
 
Trichloroethylene research has been conducted as a joint collaborative effort with the 
University of Georgia. 
 
Work on the trichloroethylene research projects has been slowed as a result of funding 
uncertainties.  The impact of these funding uncertainties has been discussed with the 
DOE.  Plans for restructuring the performance schedule of the trichloroethylene projects 
have been submitted to the department. 
 
Work on the low-dose radiation risk assessment projects is also progressing at a slowed 
rate as a result of funding.  However, it has not been necessary to restructure the 
performance schedule of these projects to date. 
 
An epidemiology project on population health risk assessment is being conducted to 
assess health risks among populations in the vicinity of the SRS.  This project is using the 
capabilities of the EBP GIS for the geographical assessment of cancer and non-cancer 
disease rates, as well as the potential association of population health risks with 
environmental exposures.  Although funding uncertainties have slowed progress on some 
aspects of this project, it has not been necessary to restructure the performance schedule 
to date. 
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Questions, comments or requests for further information concerning the activities under 
this cooperative agreement can be forwarded to Dr. Lawrence C. Mohr in the EBP office 
of the Medical University of South Carolina at (843) 792-1532. 
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1.1 Summary and Significance of Research Projects 
 
Toxicology 
 
• Trichloroethylene (TCE) is the most prevalent and widespread chemical 
contaminant at DOE sites.  TCE is regulated as a human carcinogen based upon 
its hepatocarcinogenicity in a crude mouse model.  Very little is known about the 
molecular mechanisms of carcinogenesis and the human health effects of TCE.  
MUSC has developed a comprehensive research program on the molecular 
mechanisms of disease pathogenesis and the human health effects of TCE to 
better understand the risks to workers at DOE sites.  Through this research 
program, MUSC has helped to ensure that TCE risk assessment and TCE 
remediation activities are based upon sound science.  However, as a result of 
funding uncertainties, research on TCE risk assessment has been significantly 
slowed.  Both the Medical University of South Carolina and the University of 
Georgia have provided institutional support for EBP investigators to publish the 
results of TCE risk assessment research performed through this cooperative 
agreement. 
 
Radiation Risk Assessment 
 
• The adverse health effects of both ionizing and non-ionizing radiation are of 
concern to DOE and the public.  Many important questions about the adverse 
human health effects of low-dose and low-dose rate radiation exposures remain 
unanswered – especially with respect to cancer risks.  MUSC has developed a 
comprehensive research program for the study of the effects of low-dose and low-
dose rate radiation exposures on human health.   Radiation risk assessment 
projects include the development of biologically-based models of cancer risk and 
epidemiological models of health risks following low-dose radiation exposures.  
A project is also being conducted on the assessment of both cancer and 
pulmonary fibrosis health risks following plutonium exposure. 
 
Population Risk Assessment 
 
• Population risk studies in areas surrounding DOE sites are of utmost importance 
to the department and to the citizens who live in these areas.  The Savannah River 
Region Health Information System is a very important national, regional, and 
DOE resource for the study of population health effects in the area surrounding 
the Savannah River Site.  In conjunction with the Savannah River Region Health 
Information System, MUSC has developed an extremely powerful Geographical 
Information System in which databases containing health, environmental, 
demographic and socioeconomic data can be integrated and analyzed for specific 
population health risks.  These capabilities are being used for the epidemiological 
assessment of both cancer and non-cancer health risks among populations in the 
vicinity of the Savannah River Site. 
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1.2 Program Expenditures 
 
EBP Expenditure Summary  
 
The table below reflects expenditures by budgeted category recorded for the period 
January 2008 through March 2008 and includes the total life-to-date for Cooperative 
Agreement CH11109.   
 
 
 
Budget Category  Current Period                         LTD 
    (Dollars in thousands) 
Personnel             $ 58    
Supplies        ---         
Travel         ---                                  
Other         ---                                  
Subcontract                                  ---                              
Equipment                              ---                                    
Total Direct Costs                      58                                 193                   
F & A                  15                                      77 
Total              $  73            $270 
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2.0 Program Management and Development Office 
 
The mission of the Program Management Office is to ensure that all projects of the 
cooperative agreement achieve their stated goals and objectives and are carried out in an 
efficient and cost-effective manner.  The executive leadership of the program has adopted 
a strategy-focused management approach that carefully aligns the resources and core 
competencies of the program with research priorities developed in coordination with 
DOE.  Specific Program Management responsibilities include workplan development, 
budget formulation, task organization of multidisciplinary research teams, financial 
management, progress reporting and program review. 
 
The Program Office reports to the Office of the Vice President for Academic Affairs and 
Provost.  Key faculty and staff members involved in Program Management are as 
follows: 
 
Principal Investigator and Director:  Lawrence C. Mohr, Jr., M.D. 
Co-Principal Investigator, Environmental    
Toxicology:      David Jollow, Ph.D. 
Co-Principal Investigator, Radiation     
Risk Assessment:     David G. Hoel, Ph.D. 
Co-Principal Investigator, Population    
Health Risk Assessment:    Daniel T. Lackland, Dr.P.H. 
Associate Director for Administration  
and Finance: Anita G. Jefferson, B.S. 
Administrative Coordinator:    Jill Canaday 
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3.0 Scientific Research 
 
3.1 Environmental Toxicology Research Projects 
 
 
3.1.1 Characterization of Species Differences in Trichloroethylene – Induced 
Peroxisome Proliferation and Hepatocyte Replication 
 
Project Director:     JoEllyn M. McMillan, Ph.D. 
 
Executive Summary 
 
The hepatocarcinogenicity of trichloroethylene (TCE) is thought to be related to the 
ability of its metabolites, trichloroacetic acid (TCA) and dichloroacetic acid (DCA), to 
induce peroxisome proliferative and/or hepatocyte mitogenesis in B6C3F1 mice and rats.  
Humans are considered to be less sensitive to TCE, but their susceptibility to peroxisome 
proliferation and hepatocyte mitogenesis is largely unknown.  The relative susceptibility 
of human vs. B6C3F1 mouse hepatocytes to peroxisome proliferation is of key 
importance for the use of mechanistic information in the reassessment of the carcinogenic 
risk posed by environmental TCE. Of importance, the role of the peroxisome proliferator 
activated receptor a (PPARa) in the mitogenic response is unknown. It is believed that 
differences in the levels or activity of PPARa between humans and rodents is important 
in the relative insensitivity of human hepatocytes to traditional peroxisome proliferators.  
Thus, defining the role of PPARa in the mitogenic response and delineating differences in 
PPARa activity in humans vs. rodents would contribute key mechanistic information for 
assessing the hepatocarcinogenic risk posed to humans by TCE exposure. The overall 
goal of this proposal is two fold: (1) to enhance our understanding of the epigenetic basis 
for TCE-induced hepatocarcinogenicity; and (2) to improve the assessment of relative 
risk of human vs. the B6C3F1 mouse hepatocarcinogenicity.  
 
Relevance 
  
The ability of peroxisome proliferators to induce peroxisomal and non-peroxisomal 
enzymes, the mitogenic activity of these compounds and their hepatocarcinogenic 
potential varies among species and is dependent upon the particular chemical agent being 
used. The proposed studies will provide valuable mechanistic data for determining the 
relevance of the B6C3F1 mouse model for assessing the hepatocarcinogenic potential in 
humans of TCE and other peroxisome proliferators.  The studies will provide a 
quantitative comparison of the relative responsiveness of human versus mouse and rat 
hepatocytes to peroxisome-proliferator-induced changes in activities and levels of key 
proteins and mRNAs. 
 
Objective 
 
The hepatocarcinogenicity of TCE is believed to be related to the ability of its 
metabolites, TCA and DCA, to induce peroxisome proliferative and mitogenic 
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activity in B6C3F1 mice and rats.  Humans are considered to be less sensitive, but 
their susceptibility to peroxisome proliferation and mitogenesis is largely unknown.  
The role of PPARa in peroxisomal enzyme induction in rodents is well documented.  
However its regulation of other non-peroxisomal genes is less understood.  
Differences in the levels and activity of this transcription factor have been observed 
between human and rodent liver.  Thus determining the role of PPARa activation in 
both the peroxisomal and mitogenic responses in human and rodent hepatocytes is 
important in assessing the relative hepatocarcinogenic risk to humans of TCE 
exposure.  To this end our specific aims are as follows. 
 
Specific Aim 1. To develop sensitive and selective approaches to measure the 
peroxisome proliferative and mitogenic responses in cultured liver cells 
 
Specific Aim 2. To elucidate the mechanism for the short-term in vivo hepatocyte 
replication response 
 
Specific Aim 3. To determine the involvement of the peroxisome proliferator 
activated receptor a (PPARa) in peroxisomal and cell replicative events in rodent and 
human hepatocytes. 
 
Quarterly Accomplishments 
 
Laboratory research on this project has been concluded.  Significant accomplishments  
include the development of experimental systems to conduct the following studies:  (1) 
metabolism of chloral hydrate by human hepatocytes and analysis of metabolic products 
by GC headspace analysis, (2) isolation of genomic DNA from human hepatocytes for 
ALDH and ADH genotyping, (3) genotyping of ALDH and ADH using genomic DNA 
from human hepatocytes. 
 
Performance Schedule and Status of Aims 
 
Laboratory research on this project has been concluded. 
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3.1.2 Effects of Trichloroethylene Metabolites on Hepatic Cell-Cycle Regulatory 
Proteins and Transcription Factors  
 
Project Director:        David T. Kurtz, Ph.D. 
 
Executive Summary 
 
This project explores the hypothesis that the epigenetic carcinogenicity of TCE results 
from the mitogenic activity of its metabolites. Mitogenesis may occur either via the 
peroxisomal response or by an independent mechanism. There are two specific research 
objectives: to determine how TCE metabolites cause increased cell growth and division 
in the liver and to develop quantitative tools to allow direct comparison of the 
responsiveness of humans vs. the laboratory rodent. The experimental approach will 
utilize cultured hepatocytes the B6C3F1 mouse, Long Evans and Sprague-Dawley rats, 
and long-term cultures of human hepatocytes, which have retained their differentiated 
properties. The ability of TCE and/or its metabolites to induce: cdk mRNAs and proteins; 
cyclin mRNAs and proteins; CKI mRNAs and proteins; and cyclin/cdk activity will be 
assessed. The activation of transcription factors associated with cell division (AP1, NF 
kappaB, E2F) and the inactivation of transcription factors associated with the suppression 
of cell division (C/EBP) will also be determined. To determine the importance of the 
peroxisome proliferator activated receptor (PPAR) in these inductions, the studies will 
also be carried out on hepatocytes from PPAR alpha -/- ("knockout") mice. These studies 
will provide valuable insight into the molecular basis of the non-genotoxic carcinogenic 
effects of TCE and related hazardous compounds. Furthermore, the measurements of cell 
cycle regulatory protein activity, and of transcription factors associated with cell 
proliferation, may prove to be an accurate biomarker for hepatocarcinogenesis. 
 
Relevance 
 
Trichloroethylene is a widespread contaminant at DOE sites. The toxicity of this 
compound to humans continues to be controversial. The studies outlined above should 
provide specific evidence for or against the hepatotoxicity of TCE. 
 
Objective 
 
The scientific problem being addressed in this proposal is the molecular basis for the 
hepatocarcinogenicity of TCE metabolites. The general approach will be a combination 
of biochemical, molecular biological, and cell biological techniques. To this end our 
specific aims are as follows. 
 
Specific Aim 1. To determine the molecular mechanism(s) by which TCE 
metabolites can serve as priming agents for mitogenesis in rodent hepatocytes and to 
determine if this effect can occur in human hepatocytes.  
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Specific Aim 2. To identify the effects of TCE metabolites on signal transduction 
cascades which may affect cell division in hepatocytes  
 
Specific Aim 3. To determine the effects of TCE metabolites on the activity of 
hepatocyte transcription factors which regulate cell division, and whether these effects 
require PPAR. 
 
Quarterly Accomplishments 
 
Laboratory research on this project has been concluded.  Significant accomplishments  
include: 
 
1 Characterization of the effects of DCA and TCA in inducing beta catenin/TCF 
binding to DNA in rodent liver. 
 
2 Characterization of the effects of DCA and TCA in inducing beta catenin 
nuclear translocation in human hepatoma cells. 
 
Performance Schedule and Status of Aims 
 
Laboratory research on this project has been concluded. 
 
 
3.1.3 Human and Rodent Renal Proximal Tubular Cells as Model Systems to 
Study the Toxicity and Elimination of Trichloroethylene Metabolites 
 
Project Director:     Douglas Sweet, Ph.D. 
 
Executive Summary 
 
A growing body of evidence suggests that trichloroethylene (TCE) exposure induces 
hepatocellular carcinoma, nephrotoxicity, and nephrocarcinogenicity in rats.  Further 
research has indicated that it is not the parent compound, TCE, but rather several of its 
metabolites, including trichloroacetic acid (TCA), dichloroacetic acid (DCA), and 1,2-
dichlorovinyl-L-cysteine (DCVC) that are the causative agents of the associated renal and 
hepatic toxicities.  The kidney and liver are target organs because they actively remove 
organic anions from the circulation and are therefore subject to high levels of 
accumulation of these negatively charged metabolites.  In the case of TCE, metabolite 
formation, particularly at drinking water levels, is extremely rapid and target tissue 
exposure is largely determined by the relative rates of formation of the metabolites in the 
liver and their removal from the body by the renal proximal tubule cells (RPTCs).  In 
other words, the peak metabolite concentrations and duration of exposure to the toxins 
are mostly determined by the kidney’s ability to actively remove these substances from 
the body.  Therefore, the mechanisms governing the absorption, distribution, and 
excretion of these compounds likely play a central role in their associated toxicities. 
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Two gene families expressed in the kidney and liver that mediate the transport of small 
organic anions are the Organic Anion Transporter (OAT) family and the Organic Anion 
Transporting Polypeptide (Oatp) family.  Recently, DCVC uptake by rabbit proximal 
tubules was demonstrated to be blocked by p-aminohippurate (PAH), the prototypical 
substrate for OATs.  This finding suggests the OAT family of transporters is involved in 
the absorption, distribution, and excretion of TCE metabolites (Oatps do not transport 
PAH).  In further support of this, DCVC inhibited organic anion transport mediated by 
the rabbit and human orthologs of organic anion transporter 1 (Oat1) expressed in 
heterologous cell systems. 
 
Variation in the renal elimination rate constants of the ultimate carcinogenic metabolites, 
TCA and/or DCA, is likely to be a crucial factor in physiology based pharmacokinetic 
(PBPK) modeling for sensitive populations and in risk assessment based upon such 
modeling.  Current PBPK models used in the assessment of toxicological endpoints for 
TCE exposure do not incorporate the contribution of active transport mechanisms that 
impact body compartment distribution and concentration levels, including organ-specific 
accumulation and/or secretion of TCE and its metabolites.  Therefore, the proposed 
research will quantify the contribution of active transport to the absorption and secretion 
of the acidic metabolites of TCE (TCA and DCA), as well as the metabolite DCVC, to 
increase the complexity and accuracy of PBPK models for TCE exposure. 
 
Relevance 
 
It is well known that TCA has a long plasma half-life in rodents and humans and that this 
is a major contributor to the high “area under the curve” (AUC) for TCA.  Restrictive 
binding to plasma albumen has been suggested as the molecular basis for this long half-
life.  However, recent studies have indicated that the extent of binding is less than 90% 
and hence should be non-restrictive for glomerular filtration.  An alternative explanation 
for the lack of rapid renal excretion is glomerular filtration followed by reabsorption from 
the lumen of the nephron by an active transport process.  Thus, renal organic anion 
transporters may play a significant role in determining the AUC for TCA, and hence be a 
prime determinant in the dose/response relationship for hepatocellular carcinoma.  
Knowledge of the rate constants characterizing renal transport would be helpful in 
validation of PBPK models of TCE hepatocellular carcinoma and essential in the 
identification of individuals at highest risk. 
 
Knowing which transporters are responsible for mediating the elimination and/or 
reabsorption of DCVC, TCA, and DCA would aid in the prediction and modeling of 
potential drug-xenobiotic interactions that might exacerbate or alleviate the toxic effects 
of these compounds.  Understanding the molecular basis for differing sensitivities of 
exposure between rodents and humans would aid the process of extrapolating rodent 
bioassay data to humans.  This information might also make it possible to include 
toxicogenetic parameters in risk assessment models to identify individuals/populations 
predisposed to increased risk of nephrotoxicity and hepatocarcinogenicity after TCE 
exposure.  Expression levels of the identified transporters may even serve as useful 
biomarkers for the identification of such individuals/populations. 
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Objective 
 
Preliminary investigations will determine the ability of unlabeled TCA, DCA, and 
DCVC to inhibit the function of cloned organic anion transporters expressed in 
Xenopus oocytes and transfected cultured mammalian cell lines.  Once potential 
transporters have been identified, their ability to mediate transport of radiolabeled 
TCA, DCA, and DCVC will be directly examined and the kinetic parameters of 
transport determined.  These observations will then be confirmed in intact tissue 
systems (i.e., kidney and liver slices) and isolated primary RPTC from mouse, rat, 
rabbit, and humans.  The impact that interindividual variation in transporter 
expression and function has on susceptibility to TCE induced renal and hepatic 
toxicity will also be examined. 
 
In order to establish the role active transport of TCA, DCA, and DCVC plays in their 
associated nephrotoxicity/hepatocarcinogenicity the following specific objectives will be 
addressed: 
 
Specific Aim 1. The identification of specific transporters controlling the systemic 
disposition of DCVC, TCA, and DCA in mouse, rat, rabbit, and human RPTC. 
 
Specific Aim 2. Characterization of mouse, rat, rabbit, and human transporter 
kinetic constants for DCVC, TCA, and DCA. 
 
Specific Aim 3. Assessment of potential drug-xenobiotic interactions for the 
mouse, rat, rabbit, and human transporter orthologs and their influence on the toxicity of 
DCVC, TCA, and DCA. 
 
Specific Aim 4. Incorporation of this information into PBPK models of TCA, 
DCA, and DCVC distribution for risk assessment purposes. 
 
Quarterly Accomplishments 
 
Laboratory research on this project has been concluded.  Significant accomplishments are 
delineated below: 
 
Murine primary RPTC cultures: 
 
1. We have characterized urate uptake in primary murine RPTCs for use in TCE 
(TCA and DCA) risk assessment. The urate transporter is also a Slc22a 
transporter family member and thus a candidate transporter for having potential 
interactions with TCA and DCA. 
 
2. Experiments determining the toxicity of DCVC to murine RPTCs in culture 
have been performed to (a) determine the appropriate sublethal toxic dose for 
exposure prior to mRNA collection for gene chip microarray analysis and (b) 
complement the data collected previously in the human primary RPTC model. 
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Human primary RPTC cultures: 
 
3. In vitro cytotoxicity studies examining the sensitivity of hRPTCs to sub-chronic 
exposure to DCVC have been completed.  Confluent monolayers of hRPTCs 
were treated daily with 7 different concentrations of DCVC (0, 0.1, 0.3, 1, 3, 10, 
and 30 µM) for 10 days to mimic a worker exposure situation.  The resultant 
cytotoxicity was quantitated on days 1, 3, 7 and 10 by MTT assay.  Thirty µM 
DCVC produced greater than 60% toxicity within 3 days, 10 µM produced 
greater than 75% toxicity within 7 days, and 3 µM produced ~25% toxicity in 7-
10 days.  The other concentrations were without much effect over the course of 
the experiment as assayed by MTT activity.  However, some mild effects on 
respiration were noted by day 10 with 1 µM DCVC.  Finally, sub-chronic 
exposure to DCVC produced 50% cytotoxicity in hRPTCs at 7.5 µM after 10 
days.  Therefore, 0.1 and 1 µM DCVC have been selected as the low dose and 
high dose non-cytotoxic concentrations to use in experiments aimed at 
determining the gene expression changes following exposure to sub-lethal doses 
of DCVC. 
 
4. The in vitro cytotoxicity of the glutathione conjugate DCV-GSH was also 
investigated.  Similar to DCVC, DCV-GSH at 30 µM produced ~40% toxicity 
in 3 days and greater than 60% toxicity within 7 days, and 10 µM DCV-GSH 
produced ~25% toxicity in 7-10 days.  However, all other concentrations of 
DCV-GSH were without effect. 
 
5. In vitro cytotoxicity studies with chloral hydrate (CH) have been conducted.  
Confluent monolayers of hRPTCs were treated daily with 6 different 
concentrations of CH (0, 0.03, 0.1, 0.3, 1, and 3 mM) for 10 days.  Again, the 
resultant cytotoxicity was quantitated on days 1, 3, 7 and 10 by MTT assay.  
Three mM CH produced ~25-30% toxicity within 1 day and increased to 50-
60% within 7-10 days.  Other concentrations of CH were without any 
significant consistent effect.  Thus, while CH was cytotoxic, it required 1,000-
fold higher doses than DCVC (1-3 mM over 10 days). 
 
6. The metabolism of CH (1 mM) to TCE and TCA by hRPTCs in culture has 
been observed at 1, 2, 7, and 10 days.  The percent of CH converted to TCE 
varied between ~30-60% on each day and to TCA varied from ~2-4%.  Thus, 
hRPTCs can metabolize CH to TCE and TCA. 
 
 
Performance Schedule and Status of Aims 
 
Laboratory research on this project has been concluded. 
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3.1.4 Effect of Genetic Variation and of Ethanol on the Formation of 
Trichloroacetic Acid, a Putative Hepatocarcinogenic Metabolite of TCE 
 
Project Director:     David McMillan, Ph.D. 
 
Executive Summary 
 
During this quarter we are continuing to collect and perform studies on chloral hydrate 
metabolism using human hepatocyte cultures. We have begun to observe some variability 
in the formation of TCA and TCE-OH, though more human samples will be required to 
determine the extent of the variability and the relationship to genotype. We are in the 
process of determining how many samples it will take to determine variability using 
power calculations using the known variability in the metabolism of ethanol. We also 
continue to detect the formation of DCA in human samples, and it appears that formation 
of this metabolite is real and not an artifact. We plan confirm its identity using GC/MS 
analysis in the next quarter. An abstract to the Society of Toxicology meeting on these 
data have been prepared. 
 
Relevance 
 
The utility of PBPK modeling of blood TCA levels as a dose metric for liver exposure to 
TCA after TCE ingestion is well accepted. Unfortunately, the relationship between TCE 
exposure and liver levels (AUC and peak concentrations [which may vary 
independently]) are complex and are very likely to show major differences among human 
sub-populations. These differences may underlie enhanced susceptibility (or resistance) 
by both genetic and environmental factors. The interaction of the genetic and 
environmental factors may further alter the relationship between applied dose of TCE and 
liver exposure to TCA. The proposed studies will be used in collaboration with projects 5 
and 6 to improve the reliability and applicability of PBPK modeling in the assessment of 
risk of humans to TCE. 
 
Objectives 
 
1. To determine the kinetic constants for conversion of CH to TCA and TCOH in 
hepatocytes from the target species, mice and rats (including the back reaction of 
TCOH to CH and TCA). 
2. To determine the kinetic constants for conversion of CH to TCA and TCOH in 
human hepatocytes. 
3. To characterize the isoform composition of human hepatocytes by enzymic and 
DNA array technology. 
4. To determine the effect of ethanol on the redox state of hepatocytes from mice, 
rats and humans. 
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5. To determine the effect of ethanol on conversion of CH to TCA and TCOH in 
hepatocytes from mice, rats and humans. 
 
Specific Aim 1. To determine the kinetic constants for conversion of CH to TCA 
and TCOH in hepatocytes from the target species, mice and rats (including the back 
reaction of TCOH to CH and TCA). 
 
Specific Aim 2. To determine the kinetic constants for conversion of CH to TCA 
and TCOH in human hepatocytes.  
 
Specific Aim 3. To characterize the isoform composition of human hepatocytes by 
enzymic and DNA array technology. 
 
Specific Aim 4. To determine the effect of ethanol on the redox state of 
hepatocytes from mice, rats and humans. 
 
Specific Aim 5. To determine the effect of ethanol on conversion of CH to TCA 
and TCOH in hepatocytes from mice, rats and humans. 
 
Quarterly Accomplishments 
 
Laboratory research on this project has been concluded.  Significant accomplishments  
include: 
 
1. Evaluation of cryogenically-preserved human hepatocytes for chloral hydrate 
disposition and ADH/ALDH genotype. 
 
2. Development of the ability to determine all of the single nucleotide polymorphisms 
for the ADH/ALDH enzyme systems. 
 
3. Demonstrated that there is inter-individual variation in the Vmax values for TCOH 
and TCA formation, although the disposition of chloral hydrate into these two 
competing pathways is relatively constant. 
 
4. The application of cryopreserved human hepatocytes in trichloroethylene risk 
assessment has been published in the Environmental Health Perspectives (114: 
1237-1242; 2006). 
 
Performance Schedule and Status of Aims 
 
Laboratory research on this project has been concluded.  A manuscript on 
trichloroethylene risk assessment is in preparation. 
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3.1.5 Presystemic Elimination of Trichloroethylene and its Interactions with 
Alcohol: How Important are They at Environmental Exposure Levels? 
 
Project Director:     James V. Bruckner, Ph.D. 
 
Executive Summary 
 
Although extremely high doses of trichloroethylene (TCE) are required to produce 
tumors in mice and rats, there is concern on the part of the EPA and others that even trace 
(i.e., environmental) levels may present a cancer risk to humans.  The human body has a 
number of processes to protect against such low level toxic insults, including first-pass, 
or presystemic elimination.  Volatile organic chemicals (VOCs) such as TCE that are 
absorbed from the gut are subject to metabolism by the liver and exhalation by the lungs, 
before they reach the arterial circulation and are distributed systemically.  It has been 
theorized, but not demonstrated experimentally, that all of low oral doses of VOCs are 
removed by presystemic elimination.  It will be necessary to develop very sensitive 
analytical techniques in order to conduct experiments with environmentally-relevant 
levels of TCE.  Demonstration [experimentally and by physiologically-based 
pharmacokinetic (PBPK) modeling], that all of low oral doses of TCE are eliminated, 
would have a profound effect on extrahepatic cancer and non-cancer risk assessments of 
TCE. 
 
Alcohol (i.e., ethanol) and a number of other compounds are known to stimulate 
formation of increased amounts of cytochrome P450 2E1 (CYP2E1) in the liver.  
CYP2E1 is the key enzyme that initiates the oxidation of low doses of TCE to potentially 
mutagenic metabolites.  Thus it is reasoned that drinkers metabolically activate a greater 
percentage of their systemically-absorbed dose of TCE to carcinogenic metabolites.  
Similarly, populations with genetically-determined elevations of CYP2E1 might also be 
anticipated to be at increased risk.  The EPA uses this reasoning in their most recent 
health risk assessment of TCE, to support their choice of the most conservative (i.e., 
linear, no-threshold) mathematical model to predict cancer risks.  Preliminary PBPK 
modeling efforts suggest that elevated CYP2E1 activity will not result increased 
metabolism of low, environmentally-relevant doses of TCE.  Every human has CYP2E1 
activity far in excess of that necessary to metabolize all of low doses.  Since all of trace 
amounts of TCE are metabolized, it is reasonable to conclude that increased metabolic 
capacity due to alcohol, drugs, genetics, etc. is inconsequential.  Laboratory experiments 
and PBPK modeling will be carried out to prove this hypothesis. 
 
Relevance 
 
As described above, this research project is directly relevant to current and proposed EPA 
regulatory standards for drinking water contamination by TCE.  The EPA concludes, 
through both its cancer and non-cancer risk assessments (EPA, 2001), that exposure to 
even minute levels of TCE is associated with low-level human risks.  It is concluded that 
certain subpopulations with genetically- or drug-induced elevations of P4502E1 (the 
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enzyme responsible for formation of toxic metabolites of TCE) will be at significant risk.  
Preliminary research with other well-metabolized chemicals indicates that this is not true.  
The proposed research with alcohol should definitively establish this for TCE.  The 
second low-dose phenomenon to be investigated here will be presystemic, or first-pass 
elimination.  The liver and lungs act in concert to eliminate ingested VOCs before they 
reach the systemic/arterial circulation.  It is postulated that virtually all of trace levels of 
TCE in drinking water are removed, before they reach and present a hazard to 
extrahepatic target organs such as the lungs and kidneys.  Experiments have been 
designed and a PBPK model will be developed in collaboration with Dr. Fisher to 
characterize the capacity of this protective mechanism under different TCE exposure 
conditions. 
 
Objectives 
 
1. Develop and validate assays of TCE and its major metabolites in biological 
samples, including blood, tissues and urine.  The assays should be sufficiently 
sensitive to utilize in animal experiments employing very low doses of TCE. 
 
2. Accurately determine the capacity and dose-dependency of presystemic 
elimination of orally-administered TCE.  Characterize the influence of dose 
and dosage regimen on the systemic disposition/effects of TCE and related 
VOCs. 
 
3. Establish the influence (or lack thereof) of ethanol on the metabolic activation 
of low oral doses of TCE.  Determine whether the ratio of the metabolites 
trichloroacetic acid (potentially carcinogenic) and trichloroethanol (non-
carcinogenic) is altered by ethanol. 
 
Specific Aim 1. To determine the capacity and dose-dependency of presystemic 
elimination of ingested TCE and to delineate the relative contribution of the liver and 
lungs.   
 
Specific Aim 2. To establish the influence (or lack thereof) of ethanol on the 
metabolic activation of environmentally-encountered doses of TCE. 
 
Specific Aim 3.  To determine whether the ratio of the metabolites trichloroacetic 
acid (TCA) (potentially carcinogenic) and trichloroethanol (TCOH) is altered by co-
ingestion of ethanol. 
 
Quarterly Accomplishments 
 
Work on this project has been delayed as a result of an interruption in funding.  
Significant accomplishments to date are as follows: 
  
1. One of our two original Specific Aims was to establish the influence (or lack 
thereof) of ethanol on the metabolic activation of trichloroethylene (TCE), 
 18 
including alteration of the ratio of its metabolites trichloroacetic acid (TCA) (a 
mouse carcinogen) and trichloroethanol (TCOH).  Experiments during the initial  
year of the project established that ethanol did indeed enhance the metabolism of 
relatively high doses of TCE to TCA and TCOH.  We hypothesized that induction 
of the hepatic cytochrome P450 (CYP) isozyme 2E1 (i.e., CYP2E1) would 
enhance the metabolism of high, but not low, environmentally-encountered doses 
of TCE.  Upon consideration of our results and experimental design, it became 
evident that ethanol was not only inducing CYP2E1, but altering alcohol and 
aldehyde dehydrogenases (ADH and ALDH), two enzymes responsible for  
conversion of the intermediate TCE metabolite, chloral hydrate, to TCOH and 
TCA.  Therefore, we chose to use pyridazine (PZ) rather than ethanol for the next 
phase of the project.  PZ is a potent CYP2E1 inducer, but has relatively modest  
effects on ADH and ALDH. 
 
2. Of particular importance to TCE risk assessment are two (2) important findings 
(1) PZ pretreatment resulted in a dose-dependent increase in the rate of TCE 
elimination, a substantial decrease in blood TCA levels and a modest increase in 
TCOH levels in TCE-dosed rats.  These alterations were pronounced in animals 
given 200 mg TCE/kg orally, but barely manifest at 10 mg TCE/kg, the lowest 
dosage administered.  These results support the aforementioned hypothesis about 
a lack of influence of CYP2E1 induction on low TCE doses.  A gas 
chromatography-mass spectrometry (GC-MS) method has been developed that 
will allow us to continue these experiments with much lower (i.e., 
environmentally-relevant) TCE exposures; (2) The marked reduction in blood 
TCA levels (noted above) in CYP2E1-induced animals implies that liver cancer 
risks may be lower under such conditions. 
 
3. The primary focus of our work on this project has been on clarifying the 
mechanistic basis for the substantial decrease in blood TCA concentrations in PZ-
induced rats. Progress on bringing this aspect of the project to completion has 
been delayed by funding uncertainties. 
 
4. The results of one study indicate that PZ pretreatment of rats results in a 
significant increase in the rate of clearance of TCA from the bloodstream.  Half-
lives (t½) of TCA in uninduced rats given 50 mg TCA/kg iv in two experiments 
were found to be ~800 and 930 minutes.  The t½ of TCA is much longer (3,300 
minutes) when it is formed as a metabolite in TCE-dosed animals.   This indicates 
that TCA is a rate-limited metabolite of TCE.  PZ-induced rats that received 50 
mg TCA/kg iv exhibited a TCA t½ of ~240 minutes (versus the 800- and 930-
minute t½s in uninduced rats).    This phenomenon may have resulted from:  
increased metabolism of TCA to dichloroacetic acid (DCA) and/or other 
metabolites; induction/activation of organic anion transporters in the kidneys; 
and/or displacement of TCA from plasma binding sites by PZ.   Equilibrium 
dialysis experiments have shown that PZ’s ability to displace TCA from rat 
plasma proteins is quite limited.  The highest PZ concentrations displaced only 
20% of bound TCA.  This alone cannot account for the pronounced increase in 
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TCA clearance in vivo.  Experiments are planned to assess the influence of PZ on 
urinary elimination of TCA. 
 
5. A study has also been initiated conducted to learn whether PZ pretreatment 
influences: metabolism of CH to TCA versus TCOH; and conversion of TCOH to 
TCA.  In the latter case, rats were given 50 mg TCOH/kg iv, and blood TCA 
profiles monitored for a period of hours.  TCA concentrations in blood were 
substantially lower over time in PZ-induced rats than in uninduced rats.  This may 
be due to decreased metabolism of TCOH to TCA and/or increased urinary 
excretion of TCA.  In vitro experiments are planned to determine whether the 
former occurs.  Again, work on this aspect of the project has been significantly 
delayed because of funding uncertainties. 
 
6. The following manuscripts have been published: 
 
Liu Y, Muralidhara S, Bruckner JV, Bartlett MG. Determination of 
trichloroethylene in biological samples by headspace solid-phase microextraction 
gas chromatography/mass spectrometry.  J Chromatogr B 2008; 863: 26-35. 
 
Liu Y, Muralidhara S, Bruckner JV, Bartlett MG. Trace level determination of 
trichloroethylene in biological samples by headspace solid-phase microextraction 
gas chromatography/negative chemical ionization mass spectrometry. Rapid 
Commun Mass Spectrom 2008; 22: 797-806 
 
Liu Y, Srinivasa M, Bruckner JV, Bartlett MG. In situ derivatization/solid-phase 
microextraction coupled with gas chromatography/negative chemical ionization 
mass spectrometry for the determination of trichloroethylene metabolites in rat 
blood. Rapid Comm Mass Spectrom 2008; 22: 1023-1031 
 
Performance Schedule and Status of Aims 
 
Work on this project has been delayed because of funding uncertainties. 
 
The performance schedule of this project is being restructured as a result of funding 
uncertainties.  No significant changes in the specific aims of the project are anticipated.  
A manuscript on trichloroethylene risk assessment is in preparation. 
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3.1.6 PBPK Modeling of Toxic Metabolites of Trichloroethylene in Rats, Mice and 
Humans: Predicting the Health Risks Posed by Low Level Exposure to TCE 
 
Project Director:     Jeffery W. Fisher, Ph.D. 
 
Executive Summary 
 
Trichloroethylene (TCE) remains one of the most common ground water contaminants 
found in the US because of its disposal and use practices by the private sector, DOE and 
DOD.  The projected costs for remediation of TCE in the federal sector is well over $1 B.  
The health risks of TCE were recently reviewed by several scientists and published as a 
monologue in an Environmental Health Perspectives (EHP) Supplement (Vol. 108(2), 
2000).  Since the EHP publication on TCE, the US EPA released a draft ‘regulatory risk 
assessment for TCE’ to the authors of the EHP monologue and asked the authors to 
comment on their document.  In July 2002 the US EPA convened a scientific review 
panel to review their most recent draft TCE document. Physiologically based 
pharmacokinetic (PBPK) models were used as an aid in dose-response assessment (risk 
assessment) for cancer and non-cancer toxicological endpoints.  Five PBPK models were 
used on various human and rodents studies for cancer and non-cancer endpoints.  Several 
data gaps were identified as the US EPA attempted to use the PBPK models of Fisher, 
Clewell and Barton. In some cases the PBPK models were inappropriately or 
insufficiently exercised.  The objective of this project is to develop a single robust PBPK 
model for TCE for rodents and humans by incorporating new metabolic and kinetic data 
published since 1999, and by conducting limited critical metabolic and pharmacokinetic 
experiments in rodents to fill data gaps.  The refined PBPK model for TCE and 
metabolites in laboratory animals and humans will be exercised in an appropriate manner, 
and the results will be used to reduce the uncertainties associated with assessing the 
human health risks posed by low-level environmental exposure to TCE.   
 
Much progress has been achieved in understanding the quantitative aspects of 
metabolism of TCE in humans and rodents and in understanding the toxic and 
carcinogenic potential of the acid metabolites that are formed from metabolism of TCE.  
PBPK models have progressed from models that simply describing the parent chemical to 
PBPK models that contain sub models describing the formation and kinetics of 
metabolites such as trichloroacetic acid (TCA), trichloroethanol, chloral hydrate and in 
some cases, dichloroacetic acid.   Colleagues of mine and I have developed and published 
most of the PBPK models for TCE and metabolites in humans and rodents with financial 
support from the USAF, US EPA and Strategic Environmental Research and 
Development Program (SERDP).  The US EPA used early-unpublished versions of our 
most recent PBPK models for mice and humans in their current draft risk assessment 
document.   
 
Relevance 
The scientific issues related to determining the health risks posed by low levels of TCE in 
the environment are relevant to many other solvents found in water supplies.  If sound 
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science and extrapolation methodology can be demonstrated for this chemical, then other 
chemicals can be evaluated in a similar manner.   This could lead to a potential saving of 
multiple millions of dollars in unnecessary clean-up costs. 
 
Objectives 
 
1. Harmonize current PBPK models used by the US EPA into one PBPK model for 
TCE and metabolites.  Incorporate newly published and unpublished data in 
humans and rodents.  New data sets include published and unpublished rat data on 
first pass metabolism of TCE from the laboratory of Dr. Jim Bruckner at the 
University of Georgia, published human and unpublished rat data on glutathione 
conjugation of TCE [(S-(1,2-Dichlorovinyl) Glutathione (DCVG)] obtained by 
Dr. Larry Lash at Wayne State University, and published Epidemiology studies 
performed in Europe, where urinary excretion of TCA was quantified.  
 
2. Conduct laboratory studies to refine PBPK model predicted dose metrics in 
laboratory animal and humans that will be used in the formulation of the final 
product of this project, namely a TCE human health risk assessment.  Determine 
the stoichiometric yield of DCVG for relevant doses of TCE in rats.  Information 
on DCVG will provide data to develop the DCVG pathway in a PBPK model for 
TCE and to offer plausible dose-metrics that can be associated with the risk of 
kidney cancer in humans.   Colleagues and I have time course data for DCVG in 
humans exposed to TCE vapors [Lash, LH, DA Putt, WT Brashear, R Abbas, J 
Parker and JW Fisher. 1999. Identification of S-(1,2-Dichlorovinyl) Glutathione 
in the Blood of Human Volunteers Exposed to Trichloroethylene. Toxicol. 
Environ. Health Part A, 56, 1-21].   
 
3. Conduct laboratory studies to evaluate how much dichloroacetic acid (DCA) is 
formed metabolically from TCE.  This minor metabolite remains an important 
risk assessment issue because of its carcinogenic potency and the requirement that 
the US EPA account for cumulative risks.  DCA is the number one by-product 
from chlorination of water. Thus, to account for the health risks poised by TCE in 
drinking water, the health risks from exposure to DCA itself must be quantified 
and accounted for in the health risk assessment of TCE. 
 
4. Perform a cancer and non-cancer risk assessment for TCE using the harmonized 
single PBPK model for TCE and metabolites. The risk assessment will rely on 
‘mode of action’ hypotheses and theoretical assumptions for low dose 
extrapolations. Relevant human data sets will be incorporated into the analyses.  
 
Specific Aim 1. To harmonize current PBPK models used by the US EPA into one 
PBPK model for TCE and metabolites by incorporating newly published and unpublished 
data in humans and rodents. 
 
Specific Aim 2. To examine the metabolism of TCE in rodents with emphasis on 
the dose-dependence of conversion of TCE to DCVC. 
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Specific Aim 3. To re-examine the dose-dependence of conversion of TCE to DCA 
in laboratory animals. 
 
Specific Aim 4. To perform a cancer and non-cancer risk assessment for TCE using 
the harmonized single PBPK model for TCE and metabolites. 
 
Quarterly Accomplishments 
 
Work on this project has been delayed as a result of an interruption in funding.  
Significant accomplishments to date are as follows: 
 
1. Human Dichloroacetic acid PBPK model: A model structure and metabolic 
descriptions of DCA were patterned after work in our laboratory with the 
development of a PBPK model for DCA in rats and mice. The Michaelis-Menten 
affinity constant for GSTz (Km) and enzyme degradation rate (Kde) in the model 
were fixed. The initial maximum velocity of GSTz for metabolism of DCA (Vmaxc), 
the non-metabolism loss rate (Kfc), inhibition rate (kd) and oral absorption rates were 
estimated through fitting DCA blood kinetic data sets from different human clinic 
studies.  
 
Several published kinetic studies exist for DCA. Additionally, we are using new 
unpublished low dose pharmacokinetic data collected with 8 males and 8 females 
under an EPA grant at Battelle NW. These individuals were given a single iv dose 
(0.3 mg/kg) followed by a 2 mg/kg oral dose at the beginning of the study and then 
repeated14 days later.  The subjects drank 0.02 mg/kg DCA for 14 consecutive days 
between the two doses.  
 
The human DCA kinetic model suggests the polymorphic forms of GSTz and oral 
absorption rates influence the kinetics of DCA. Our simulations also suggest that 
DCA is degraded by another unknown metabolic pathway as proposed in our DCA 
modeling with rats and mice. 
 
2. Two trichloroacetic acid (TCA) modeling papers are being finalized for publication to 
journals. One paper describes the influence of serum protein binding on the dosimetry 
of TCA in liver of mice and humans. The other paper evaluates the pharmacokinetic 
evidence that TCA is the primary metabolite responsible for liver tumors in mice. 
 
3.  The following manuscript has been published: 
 
Li T, Schultz I, Keys DA, Campbell JL, Fisher JW. Quantitative evaluation of 
dichloroacetic acid kinetics in human – a physiologically based pharmacological 
modeling investigation. Toxicology 2008: 245; 35-48 
 
 23 
 
Performance Schedule and Status of Aims  
 
Work on this project has been delayed because of an interruption in funding. 
 
The performance schedule of this project is being restructured as a result of funding 
uncertainties.  No significant changes in the specific aims of the project are anticipated. 
 
 
3.2 Radiation Risk Assessment Projects 
 
3.2.1 Low Dose Radiation: Biologically-Based Models of Cancer Risk 
 
Project Director:      David G. Hoel, Ph.D. 
 
Executive Summary 
 
The use of experimental animals in radiation risk estimation is especially important for 
those situations when human data are inadequate or unavailable.  This is particularly true 
for neutron exposures and low-dose rate exposures to gamma and x-ray.  The purpose of 
this project is to apply biological based models to radiation risk estimation using 
experimental data.   
 
The important questions to be answered are 1) whether or not non-cancer effects such as 
cardiovascular disease (CVD) are effected by low doses of radiation. 2) What is the 
increase in risk for a equivalent dose of alpha or neutron compared to gamma or x-ray? 3) 
Is the risk of chronic radiation exposure the same as that of acute exposure of both high 
LET (alpha, neutron) and low LET (gamma, beta, x-ray) exposures.  4) Are cancer and 
non-cancer effects present at low doses of radiation (neutron, alpha and gamma)? 
 
Relevance 
 
By comparing the two stage clonal expansion models for cancer with the in vivo 
experimental data, the investigators will not only increase understanding of cancer 
development following low-dose radiation exposure, but also add biological credibility. 
This approach will provide a method for answering the important environmental question 
of whether risks are decreased with decreasing dose-rate, a key issue for chronic radiation 
control of workplace exposures.  Further, the effects of neutron and alpha exposure at 
low-doses is of importance to radiation workers. 
 
Objectives 
 
The objective of this project is to determine the effects of dose-rate and radiation type on 
the development of various cancer types following low-dose radiation exposures. Two-
stage biologically based risk models will be used for analysis and compared with the 
results from traditional methods of analysis. Using previously validated data, assumptions 
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made about the biological effects of ionizing radiation can be used in the two-stage model 
to predict dose-rate effects on the development of various cancers following low-dose 
exposures.  Additionally non-cancer effects such as cardiovascular disease will be 
estimated at low doses of radiation. 
 
Specific Aim 1. To use the large Argonne National Laboratory Janus mouse study 
to answer basic questions concerning dose-rate and radiation type effects on cancer.  This 
involves over forty thousand mice exposed acutely and chronically at several doses with 
both gamma or neutron exposures. 
 
Specific Aim 2. To use the data from new studies at the Bologna Institute of 
Oncology (Italy) on gamma exposed Spague-Dawley rats.  This data will provide for the 
estimation of low-dose effects of gamma exposures.  These studies involve both acute 
and chronic exposures. 
 
Specific Aim 3. To use this data from the Harwell Laboratory (U.K.), which 
involves alpha and beta radiation by inhalation and injection exposures to mice.  These 
studies provide an accurate comparison of the cancer effects of alpha exposure to that of 
beta. 
 
Quarterly Accomplishments 
 
Specific Aim 1- Work is progressing on the analysis of mouse data from Argonne 
National Laboratory with respect to  gamma and neutron effects on life-shortening and 
the development of hematapoietic cancers. 
 
Specific Aim 2 -  Manuscripts are being prepared regarding the analysis of data from 
acute low-dose gamma exposures to Sprague-Dawley rats.  A second large study 
involving chronic low-dose gamma exposures to Sprague-Dawley rats has been 
completed and work is progressing on the evaluation of  histopathology in preparation for 
data analysis. 
 
Data analysis for the two stage clonal expansion model is progressing.  We will apply the 
analysis to available animal data (Argonne, Harwell, Bologna) for improved cancer risk 
estimates. Progress continues to be made on the analysis of the Argonne mouse neutron 
data. 
 
Performance Schedule and Status of Aims 
 
Neither the performance schedule nor the status of aims has changed. 
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3.2.2 Low Dose Radiation: Epidemiological Risk Models 
 
Project Director:      David G. Hoel, Ph.D. 
 
Executive Summary 
 
The data used for estimating health risk from low LET radiation (e.g. x-ray, gamma) has 
been obtained from the A-bomb survivor cohort.  This group, along with some cohorts of 
high dose medically exposed individual’s makes up our source of information.  Two 
important issues are of current concern: 1) Does the risk of cancer follow a linear dose-
response at low-doses?, 2) Are individuals exposed at older ages (i.e. greater than 45 
years) more susceptible to developing cancer than expected?, 3) What are the non cancer 
radiation effects? 
 
We have shown that the cancer risks at low-doses based upon the A-bomb data over 
estimates cancer risk.  We have incorporated errors in dosimetry into the analysis of 
cancer risk and are proceeding to evaluate the risk at low doses of radiation exposure. 
 
Relevance 
 
Using Japanese A-bomb survivor data, the investigators seek to refine our understanding 
of the mathematical relationship between health outcomes (cancer and non cancer) data 
and exposures to low-dose radiation.  The issue of whether the relationship is linear or 
non-linear continues to be controversial.  This project will address this very important 
scientific issue. 
 
Objectives 
 
The shape of the dose-response function for radiation-induced cancer and non-cancer 
effects in humans has depended primarily on data obtained from the Japanese A-bomb 
survivors. This project will re-examine these data with respect to the linearity of cancer 
risks from low dose (1-10 rem) radiation exposures. An analysis of A-bomb survivor data 
for solid tumors and leukemia indicates that there is a non-linear relationship to 
carcinogenesis following low-dose radiation exposure. Uncertainty in the dose estimates, 
including underestimation of neutrons and a relative biological effectiveness (RBE) that 
varies with dose are being incorporated into this low-dose analysis.  A comprehensive 
and focused analysis of epidemiological data from Japanese A-bomb survivors will 
greatly increased our understanding of the true epidemiological relationship between 
cancer and non-cancer risks and low-dose radiation exposure. In addition, DOE worker 
data which has been reported as providing the scientific basis for an increased 
susceptibility from exposure at older ages will be evaluated and contrasted with the A-
bomb data. 
 
Specific Aim 1. To carefully perform statistical modeling of the available 
epidemiological data from the A-bomb survivor cohort in order to increase our 
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understanding of the cancer and non-cancer health risks related to low-dose radiation 
exposure.  
 
Specific Aim 2. The DOE worker data from CEDER (DOE’s data repository) will 
be used to evaluate the effect of exposures at older ages and reported increased cancer 
risk following low-dose radiation exposure.  The entire set of available worker data will 
be modeled in order to evaluate the older age issue.  The results of the worker analysis 
will then be compared to the analysis of the acutely exposed A-bomb survivors. 
 
Quarterly Accomplishments 
 
1. Progress continues to be made on the statistical modeling of the A-bomb 
survivor data for the assessment of both cancer and non-cancer health risks. 
 
2. A draft manuscript on the assessment of cardiovascular disease risk based 
upon the Janus mouse data from Argonne National Laboratory is under review 
for scientific journal submission. 
 
Performance Schedule and Status of Aims 
 
Neither the performance schedule nor the status of aims has changed. 
 
 
3.2.3 Health Risks of Plutonium Exposures 
 
Project Director:      David G. Hoel, Ph.D. 
 
Executive Summary 
 
Human data on health risks associated with internal exposure to radionucleides (by 
inhalation and/or ingestion) is limited. With regard to plutonium exposures, there have 
been two DOE worker studies and, more recently, several studies of Russian nuclear 
workers (Mayak). One of the DOE worker cohorts (Rocky Flats) contains data that may 
be very useful in understanding the carcinogenic effects of low-dose plutonium exposure. 
In contrast to the paucity of human data, there is a considerable amount of experimental 
data related to the development of cancer in rats and dogs following plutonium 
inhalation. A statistical model of cancer risk following low-dose plutonium exposure is 
becoming increasingly important with respect to planned DOE material disposition 
activities, both domestic and international. For example, plans to eliminate surplus U.S. 
plutonium during the next two decades, through the irradiation of mixed oxide fuel and 
the conversion of a certain portion of the material to an immobilized waste form, 
represent significant program initiatives. It is particularly important for potential health 
effects of these initiatives to be investigated and to be incorporated into evolving 
statistical risk models.  U.S. data will be related to prior studies of the Mayak workers 
which have consistently shown a higher level of lung, liver and bone cancer in 
comparison to U.S. workers.  Pulmonary fibrosis is also a risk from the inhalation of 
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plutonium; factors related to this risk will be assessed through the analysis of available 
animal and human data. 
 
Relevance 
 
The processing and storage of plutonium requires a quantitive understanding of the health 
risks of plutonium, particularly in the low-dose range. Furthermore, DOE workers who 
may be exposed to plutonium should be monitored with a state-of-the-art medical 
surveillance program that includes the use of validated biomarkers. 
 
Objectives 
 
1. The general problem we are considering is the evaluation and protection of the 
health of DOE workers in their handling of plutonium at the SRS and other DOE 
facilities. The project will develop risk models of the cancer and non-cancer 
health effects of low dose plutonium exposures, to include low-dose exposures by 
inhalation or ingestion.  These risk models will be used for the subsequent 
development of an appropriate medical and environmental surveillance system. 
 
2. The first step is a quantitative evaluation of the human and animal data so that we 
have good productive risk models.   
 
3. We will develop a medical and environmental surveillance system which includes 
the use of urine analyses for the measurement of internal plutonium levels.  
 
Specific Aim 1. To develop human risk models for cancer and non-cancer health 
effects of plutonium exposure, to include low-dose exposures by inhalation or ingestion. 
  
Specific Aim 2.  To develop a medical and environmental surveillance system for 
DOE workers who may be exposed to plutonium, to include low dose exposures by 
inhalation or ingestion.  This system will be based upon the risk models developed in 
Specific Aim 1. 
 
Quarterly Accomplishments 
 
1. Progress continues to be made on the analysis of data from beagle dogs exposed 
to plutonium-238 and plutonium-239 via inhalation.  The analysis of beagle dog 
data for lung cancer and lung fibrosis incidence following exposure to these two 
isotopes of plutonium via inhalation has been completed.  A draft manuscript has 
been completed. 
 
2. The time-dependent dose-response models for the incidence of lung cancer and 
lung fibrosis following exposure to plutonium-238 and plutonium-239 have been 
completed.  A manuscript is being prepared. 
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3. Lung cancer and lung fibrosis risk modeling from the beagle dog data has been 
completed.  A manuscript is being prepared. 
 
4. The analyses of human data from the Mayak and Rocky Flats worker cohorts is 
underway. 
 
5. The development of risk modeling methodology for the application of animal 
data to human risk assessment is underway.  
 
Performance Schedule and Status of Aims 
 
Neither the performance schedule nor the status of aims has changed. 
 
3.3 Population Health Risk Assessment Project 
 
 
3.3.1 Population Health Risks in The Vicinity of the Savannah River Site Using 
Geographic Information System Technology 
 
            Project Director:  Daniel Lackland, Dr.P.H. 
 
Executive Summary 
 
The analytical assessment of disease patterns is a critical component in the investigation 
of the environmental etiology of disease and associated population health risks.  Such 
analyses involve complex and sophisticated quantitative methodology.  EBP 
investigators have developed and are sophisticated, validated analytical techniques and 
technology to investigate population health risks.  This project will use the powerful 
capabilities of the EBP geographical information system (GIS), which is capable of 
incorporating multiple health outcomes data bases and environmental data bases, to 
detect and analyze both cancer and non-cancer population health risks that may occur 
among communities in the vicinity of the Savannah River Site (SRS). 
 
EBP investigators have continually improved the analytical capabilities of the GIS and 
have produced numerous publications and reports on the health assessment of 
populations who live in the vicinity of the SRS.  These investigations have included both 
cancer and non-cancer disease outcomes and their association with environmental and 
occupational exposures.  Exposure assessments have included chemical, radiation and 
potentially hazardous air exposures, as well as exposures to natural elements, such as 
sodium, in drinking water.  Research has also been conducted on the poorly understood 
association between electromagnetic field exposures and disease risks. 
 
This project continues to focus on epidemiological investigations of cancer and non-
cancer health risks among geographically defined populations who live in the vicinity of 
the SRS.  The ongoing analysis of cancer data pertaining to specific geographically-
defined populations in proximity to the SRS is essential to understanding any increases in 
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cancer risk that may be occurring among these populations.   Non-cancer population 
health risks among populations in the vicinity of the SRS are also being investigated.  
Using the capabilities of the EBP GIS, potential associations of both cancer and non-
cancer population health risks with environmental exposures are also being investigated.  
These population health risk studies will provide valuable epidemiological information to 
both DOE and communities in the vicinity of the SRS regarding concerns about 
population health risks that may be associated with environmental exposures.  
Conversely, the absence of any significant population health risks or environmental will 
be reassuring to these communities. 
 
Relevance 
 
The ability to accurately monitor and assess health risks among populations that live in 
the vicinity of SRS is of utmost importance to the DOE, as well as to communities in the 
vicinity of the SRS.  An important aspect of this project will be to inform both DOE and 
communities in the vicinity of the SRS of any significant population health risks that are 
identified.  Should there be an increase in the rate of cancer and non-cancer health risks 
the Savannah River Region in the future, MUSC will be able to detect the increase, 
ascertain the magnitude of the increase, investigate possible environmental causes and 
accurately inform both DOE and the public of these risks.  Conversely, EBP research will 
be able to inform both DOE and the public of the absence of significant population health 
risks in the vicinity of the SRS when they are found to be nonexistent.  In the past such 
information has been reassuring to communities in the vicinity of the SRS.  In addition to 
providing important information for risk communication, the results of this project will 
help to facilitate accelerated clean-up by the enhancement of risk-based decision making 
and the establishment environmental management priorities that are based upon sound, 
up-to-date science. 
 
The methodology developed and used by EBP for the assessment of health risks among 
populations near the SRS can be used as “templates” for studies of health risks among 
populations near other DOE sites, other government installations and industrial facilities 
that contain potentially hazardous materials.  As previously briefed to DOE, EBP has the 
capability to use its GIS and analytical techniques to monitor and assess population 
health risks among communities in the vicinity of other DOE sites. 
 
Objectives 
 
Specific Aim 1: To continue the assessment of population cancer risks among 
geographically defined populations in the vicinity of the SRS. 
 
Specific Aim 2:  To continue the assessment of non-cancer population health risks among 
geographically defined populations in the vicinity of the SRS. 
 
Specific Aim 3: To continue the assessment of cancer and non-cancer population health 
risks in relation to potentially hazardous environmental exposures among geographically 
defined populations in the vicinity of the SRS. 
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Quarterly Accomplishments 
 
Specific Aim 1:   Progress continues to be made on the epidemiological analysis of 
cancer rates among populations in the vicinity of the SRS.  Data continues to be collected 
on cancer rates among former SRS workers.  Progress continues to be made on the 
geographic distribution and epidemiological analyses of cancer rates among populations 
in comparison to the geographic location of cancer prevention services. 
 
Specific Aim 2:  A draft manuscript has been prepared on the geographic assessment of 
Parkinson’s disease rates among rural and poor residents who live in the vicinity of the 
SRS.  This manuscript is undergoing review for scientific journal submission.  Data is 
also being collected for the geographic assessment and epidemiological analysis of 
Systemic Lupus Erythematosis (SLE) rates among populations in the vicinity of the SRS.  
Progress is being made on the collection of cardiovascular disease data on former SRS 
workers. 
 
Specific Aim 3:  Based upon a recent report of an association between trichloroethylene 
exposure and Parkinson’s disease, research plans are being developed to investigate 
possible epidemiological associations between Parkinson’s disease rates among 
populations in the vicinity of the SRS and environmental trichloroethylene exposures 
using our GIS capabilities.  SLE has also been associated with trichloroethylene 
exposure.  Plans are being made to investigate possible epidemiological associations 
between SLE rates among populations in the vicinity of the SRS and environmental 
trichloroethylene exposures using our GIS capabilities.  Progress is being made on the 
preparation of a manuscript on the epidemiological analysis of heath effects of former 
SRS workers in comparison to multiple environmental exposures. 
 
Performance Schedule and Status of Aims 
 
Neither the performance nor the status of aims has changed.  
 
 
 
 
 
 
